Background For favorable-and intermediate-risk AML patients who lack of an available HLA-
matched donor, the post-remission treatment is controversial. Autologous stem cell …

Stem cell transplantation (SCT) is an attractive postremission treatment option for patients
with intermediate-risk acute myeloid leukemia (AML) and for some favorable-risk AML …

Background Optimal post-remission strategy for patients with acute myeloid leukemia (AML)
is matter of intense debate. Recent reports have shown stronger anti-leukemic activity but …

Background. Optimal post-remission strategy for patients with acute myeloid leukemia (AML)
is still matter of debate. Allogeneic Stem Cell Transplant (allo-HSCT) is the most effective …

Methods We identified and analyzed 57 patients (33 male) with AML who received a 2 nd
allogeneic HSCT at our center between 2000 and 2022. Median age at 2 nd HSCT was 55.5 …

Introduction Autologous hematopoietic stem cell transplantation (auto-HSCT), matched
sibling donor HSCT (MSD-HSCT), and alternative donor HSCT (AD-HSCT) are viable post …

Allogeneic hematopoietic stem-cell transplantation (allo-SCT) has an established role in the
treatment of patients with acute myeloid leukemia (AML). Although the majority of adult …

Autologous hematopoietic stem cell transplantation (auto‐HSCT), matched sibling donor
HSCT (MSD‐HSCT), and alternative donor HSCT (AD‐HSCT) are viable post‐remission …

Abstract 1974 Most available data on the relative value of allogeneic stem cell
transplantation (allo-SCT) for acute myeloid leukemia (AML) in first complete remission …

Background Achieving complete remission (CR) is the main goal in AML treatment and a
prerequisite for successful autologous stem cell transplantation (ACT). Methods Comparing …